Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on intelligent, rapid, non-invasive testing solutions, with a primary emphasis on its Intelligent Fingerprinting Drug Screening System. The INBS news feed on Stock Titan aggregates company announcements, press releases and related coverage so readers can follow developments around its fingerprint-based drug screening platform, partnerships and capital markets activity.
Recent news highlights include record fiscal 2026 first quarter revenue driven by consumable cartridge sales, the addition of dozens of new customer accounts across more than 24 countries, and large deployments with organizations in sectors such as industrial services and public transport. Updates also cover the company’s razor–razor-blade business model, where installed readers support recurring cartridge revenue, and its efforts to expand adoption in safety-critical industries like construction, manufacturing and engineering, transport and logistics, mining and government administration.
INBS news items frequently address strategic partnerships and manufacturing, such as the collaboration with Syrma Johari MedTech Ltd to scale production of the Intelligent Fingerprinting Drug Screening Reader, and the alliance with Vlepis Pty Ltd to explore wearable patch technologies and consumer health monitoring. Additional coverage includes the distribution agreement for the SmarTest Patch, a 7–10 day continuous drug monitoring solution, and updates on regulatory pathways, including anticipated FDA 510(k) submissions.
Investors can also track capital structure and listing-related developments, including reverse stock split decisions, Nasdaq bid price deficiency notices and private placement financings with institutional investors. By reviewing the INBS news stream, readers gain context on how Intelligent Bio Solutions is executing its commercial strategy, expanding its customer base, managing manufacturing partnerships and addressing regulatory and listing requirements over time. Bookmark this page to quickly access the latest official communications and market-moving updates related to INBS.
Intelligent Bio Solutions (Nasdaq: INBS) showcased its Intelligent Fingerprinting Drug Screening Solution at the UK's premier Health & Safety Event 2024. The event, featuring over 250 exhibitors and 11,500 attendees from major brands like Amazon and Rolls Royce, provided a platform for INBS to demonstrate its innovative technology. Key decision-makers, who constituted 77% of attendees, engaged with the solution, noting its pivotal role in enhancing workplace safety. Live demonstrations with clients like Stewart Osmond from WTW highlighted the technology's effectiveness in combating drug driving in the logistics sector. Discussions with a South American distributor suggested potential expansion into Chilean hospitals and emergency services. The event was marked as the most successful yet by INBS, validating the necessity and global relevance of their drug screening technology.
Intelligent Bio Solutions Inc. (INBS) reported an 80% increase in revenue for the fiscal third quarter and a 193% increase for the nine months ended March 31, 2024. Cash and cash equivalents stood at $9.40 million. The company started FDA 510(k) clinical studies with Cliantha Research and aims for US entry in 2025. INBS secured 26 new customer accounts, totaling around 16,779 employees. The total revenue for the fiscal third quarter was $0.82 million, a 80% hike from the previous year. A net loss of $2.98 million was reported, including non-cash expenses. The Company raised approximately $10.76 million in the fiscal quarter. Financial highlights include growth in revenue from sales of goods and a decrease in net loss attributable to INBS. Operational highlights consist of significant partnerships and a new European patent for its technology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.